Dr. Shah on Trials Examining Cilta-Cel in Relapsed/Refractory Multiple Myeloma

Partner | Cancer Centers | <b>RWJBarnabas Health and Rutgers Cancer Institute of New Jersey</b>

Mansi R. Shah, MD, discusses ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma.

Mansi R. Shah, MD, hematologist/oncologist, Rutgers Cancer Institute of New Jersey, assistant professor of medicine, Rutgers Robert Wood Johnson Medical School and attending at Robert Wood Johnson University Hospital, discusses ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with relapsed or refractory multiple myeloma.

At the Rutgers Cancer Institute of New Jersey, many clinical trials are available to patients with relapsed or refractory disease, including a study examining cilta-cel, according to Shah. Currently, idecabtagene vicleucel (ide-cel; Abecma) is the only CAR T-cell therapy that is FDA approved for this patient population and wait lists to receive this product are long because the demand for this treatment has outweighed the supply, Shah says.

Cilta-cel is available to patients in a clinical trial setting for use in different lines of therapy, Shah adds. The trial that is being done at the instate provides patients with the opportunity to receive treatment with the novel modality, Shah concludes.